文献速递头颈PETCT

PET/CT在头颈部鳞状细胞癌管理中的临床实践

Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer.
PubMed 文献 · AJR Am J Roentgenol · 2017-01-01

本文总结FDG PET/CT在头颈部鳞状细胞癌管理中的证据并建议最佳临床实践。FDG PET/CT可用于寻找原发灶、III/IV期初始分期、放化疗至少12周后评估疗效及避免不必要的计划性颈淋巴结清扫,不推荐无临床怀疑时常规监测。

要点

  • FDG PET/CT是III和IV期头颈部鳞状细胞癌初始分期的标准诊疗。
  • 放化疗至少12周后行FDG PET/CT评估疗效,阴性者无论残余淋巴结大小均避免颈淋巴结清扫。
  • 不鼓励治疗后6个月无临床怀疑时用FDG PET/CT常规监测。

核心结论

  • FDG PET/CT是识别已知颈部淋巴结转移患者原发灶的有价值工具并可改变管理,是III和IV期头颈部鳞状细胞癌初始分期、放化疗至少12周后评估疗效及避免不必要的计划性颈淋巴结清扫的标准诊疗;临床怀疑复发或转移时随访中有价值,并可作为患者5年生存结局的预后标志物;不鼓励治疗后6个月无临床怀疑时常规监测。

研究设计与样本

  • 本文为综述,总结FDG PET/CT用于头颈部鳞状细胞癌管理的证据并建议最佳临床实践。

诊断标准与关键数值

  • FDG PET/CT用于识别已知颈部淋巴结转移患者的原发灶可导致管理改变。
  • FDG PET/CT是III和IV期头颈部鳞状细胞癌初始分期的标准诊疗。
  • 放化疗至少12周后行FDG PET/CT评估疗效。
  • PET/CT阴性时无论残余颈部淋巴结大小均避免颈淋巴结清扫,因生存结局不受影响。
  • 不鼓励治疗后6个月无临床怀疑时用FDG PET/CT常规监测。

临床应用与阅片要点

  • 已知颈部淋巴结转移者可用FDG PET/CT寻找原发灶以改变管理。
  • III和IV期头颈部鳞状细胞癌初始分期采用FDG PET/CT作为标准诊疗。
  • 放化疗至少12周后行FDG PET/CT评估疗效,阴性者无论残余淋巴结大小均避免颈淋巴结清扫。
  • 临床怀疑复发或转移时随访中用FDG PET/CT检测,并可作为5年生存结局的预后标志物。
  • 不鼓励治疗后6个月无临床怀疑时用FDG PET/CT常规监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this article is to summarize the evidence for the value of PET/CT for the management of patients with head and neck squamous cell cancer and suggest best clinical practices.

CONCLUSION: FDG PET/CT is a valuable imaging tool for identifying unknown primary tumors in patients with known cervical node metastases leading to management change and is the standard of care for the initial staging of stage III and IV head and neck squamous cell carcinomas (HNSCCs), for assessing therapy response when performed at least 12 weeks after chemoradiation therapy, and for avoiding unnecessary planned neck dissection. Neck dissection is avoided if PET/CT findings are negative-regardless of the size of the residual neck nodes-because survival outcomes are not compromised. FDG PET/CT is valuable in detecting recurrences and metastases during follow-up when suspected because of clinical symptoms and serves as a prognostic marker for patient survival outcomes, for 5 years. Using FDG PET/CT for routine surveillance of HNSCC after 6 months of treatment without any clinical suspicion should be discouraged.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Goel R, Moore W, Sumer B, et al. Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. AJR Am J Roentgenol. 2017. PMID: 28731808. doi:10.2214/AJR.17.18301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。